Name: Focus on systemic therapy for ovarian clear cell carcinoma by ESMO Podcasts
Duration: 15 min 38 s
Description: In this podcast, Dr Maria Kfoury, of Institut Paoli-Calmettes (IPC), Marseilles, France, and Professor David Tan, of the National University Cancer Institute, Singapore, discuss developments in research in the systemic therapy of ovarian clear cell carcinoma: Are there any specific issues, and should they be treated separately?

Professor Johan Vansteenkiste, an associate Editor of Annals of Oncology, discusses the recent publication of Felip et al. that reports a study of the intracranial, and extracranial efficacy of lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI)in ALK-positive NSCLC that progressed on second-generation ALK TKIs.
Felip E et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.02.012
Stinchcombe TE. Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.  Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.03.002

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive NSCLC

In this podcast, Dr Maria Kfoury, of Institut Paoli-Calmettes (IPC), Marseilles, France, and Professor David Tan, of the National University Cancer Institute, Singapore, discuss developments in research in the systemic therapy of ovarian clear cell carcinoma: Are there any specific issues, and should they be treated separately?

Focus on systemic therapy for ovarian clear cell carcinoma

Professor Florian Lordick discusses his recent editorial in Annals of Oncology that considered the results of theARTIST 2 and CRITICS trials in gastric cancer, both published in the March issue of the journal.
Adjuvant radiotherapy for gastric cancer—end of the road? F. Lordick, M. Nilsson & T. Leong https://doi.org/10.1016/j.annonc.2020.12.006
ORIGINAL ARTICLEAdjuvant chemotherapy is superior to chemoradiation after D2 surgery forgastric cancer in the per-protocol analysis of the randomized CRITICS trial. W. O. de Steur, R. M. van Amelsfoort, H. H. Hartgrink et al. https://doi.org/10.1016/j.annonc.2020.11.004
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. S. H. Park, D.H.Lim, T. S. Sohn et al. https://doi.org/10.1016/j.annonc.2020.11.017

Adjuvant radiotherapy for gastric cancer?

OncologyPRO: The home of ESMO’s educational and scientific resources. Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.

Focus on systemic therapy for ovarian clear cell carcinoma

ESMO Podcasts

Related tracks